Read by QxMD icon Read

Journal of the American Society of Hypertension: JASH

Marcel Wilhelm, Alexander Winkler, Winfried Rief, Bettina K Doering
Hypertension is often treated pharmacologically. Since there is evidence that the cardiovascular system is sensitive to placebo mechanisms, our aim was to conduct an effect size analysis of placebo groups in double-blinded randomized controlled parallel-group drug trials using beta-blockers to treat hypertensive patients. A comprehensive literature search via PubMed, PsycINFO, PSYNDEX, PQDT OPEN, OpenGREY, ISI Web of Knowledge, and the WHO International Clinical Trials Registry Platform provided the basis of our meta-analysis...
November 5, 2016: Journal of the American Society of Hypertension: JASH
Alejandro de la Sierra, José R Banegas, Juan A Divisón, Manuel Gorostidi, Ernest Vinyoles, Juan J de la Cruz, Julián Segura, Luis M Ruilope
We aimed to characterize 24-hour blood pressure (BP) values and categories in patients with inclusion/exclusion criteria of the Systolic Blood Pressure Intervention (SPRINT) trial from the Spanish ABPM Registry. We selected patients older than 50 years, with office systolic BP (SBP) above 130 mm Hg and at high cardiovascular risk, but without diabetes, previous stroke, or symptomatic heart failure. Ambulatory BP was compared among BP categories. A total of 39,132 patients (34%) fulfilled inclusion criteria of SPRINT trial...
November 5, 2016: Journal of the American Society of Hypertension: JASH
Jae-Hong Ryoo, Sung Keun Park, Chang-Mo Oh, Young-Jun Choi, Ju Youn Chung, Woo Taek Ham, Taegi Jung
Despite the accumulated evidence showing the significant association between hypertension and obesity, it remains unclear how metabolic healthy status of obesity have an impact on the development of hypertension. Thus, this study was to investigate the risk of hypertension according to the metabolic healthy status stratified by the degree of obesity. A cohort of 25,442 Korean men without hypertension at baseline was followed-up from 2005 to 2010. They were divided into the following 6 phenotypes according to their baseline metabolic health and obesity status: metabolically healthy normal weight (MH-NW), metabolically healthy overweight (MH-OW), metabolically healthy obese (MHO), metabolically unhealthy normal weight (MU-NW), metabolically unhealthy overweight (MU-OW), and metabolically unhealthy obese (MUO)...
November 2, 2016: Journal of the American Society of Hypertension: JASH
Baris Afsar, Nosratola D Vaziri, Gamze Aslan, Kayhan Tarim, Mehmet Kanbay
Increased blood pressure (BP) and chronic kidney disease are two leading risk factors for cardiovascular disease. Increased sodium intake is one of the most important risk factors for development of hypertension. Recent data have shown that gut influences kidney function and BP by variety of mechanisms. Various hormones and peptides secreted from gut such as gastrin, glucocorticoids, Glucagon-like peptide-1 impact on kidney function and BP especially influencing sodium absorption from gut. These findings stimulate scientist to find new therapeutic options such as tenapanor for treatment of hypertension by blocking sodium absorption from gut...
November 1, 2016: Journal of the American Society of Hypertension: JASH
Phillip D Levy, Robina Josiah Willock, Michael Burla, Aaron Brody, James Mahn, Alexander Marinica, Samar A Nasser, John M Flack
Predicting blood pressure (BP) response to antihypertensive therapy is challenging. The therapeutic intensity score (TIS) is a summary measure that accounts for the number of medications and the relative doses a patient received, but its relationship to BP change and its utility as a method to project dosing equivalence has not been reported. We conducted a prospective, single center, randomized controlled trial to compare the effects of Joint National Committee (JNC) 7 compliant treatment with more intensive (<120/80 mm Hg) BP goals on left ventricular structure and function in hypertensive patients with echocardiographically determined subclinical heart disease who were treated over a 12-month period...
October 28, 2016: Journal of the American Society of Hypertension: JASH
Marcela A Casanova, Fernanda Medeiros, Michelle Trindade, Célia Cohen, Wille Oigman, Mario Fritsch Neves
Association between hypertriglyceridemia and cardiovascular (CV) disease is still controversial. The purpose of this study was to compare omega-3 and ciprofibrate effects on the vascular structure and function in low and high CV risk hypertensive patients with hypertriglyceridemia. Twenty-nine adults with triglycerides 150-499 mg/dL were divided into low (<7.5%) and high (≥7.5%) CV risk, randomized to receive omega-3 fatty acids 1800 mg/d or ciprofibrate 100 mg/d for 12 weeks. Treatment was switched after 8-week washout...
October 26, 2016: Journal of the American Society of Hypertension: JASH
Martin G Myers, Norm R C Campbell
SPRINT reported significantly fewer cardiovascular events when patients with a higher cardiovascular risk were treated to a target systolic blood pressure (BP) of <120 versus <140 mm Hg. In SPRINT, BP was recorded using the automated office BP (AOBP) method, with multiple readings being taken automatically with the patient resting alone. This technique for BP measurement eliminates the white-coat effect and gives lower BP readings than conventional manual office BP. Critics have questioned if the readings were actually taken with the subject alone and have expressed concerns about the time taken to obtain the readings and the cost of automated sphygmomanometers...
October 21, 2016: Journal of the American Society of Hypertension: JASH
David G Reuter, Yuk Law, Wayne C Levy, Stephen P Seslar, R Eugene Zierler, Mark Ferguson, James Chattra, Tim McQuinn, Lenna L Liu, Mark Terry, Patricia S Coffey, Jane A Dimer, Coral Hanevold, Joseph T Flynn, F Bruder Stapleton
The morbidity and mortality associated with preeclampsia is staggering. The physiology of the Page kidney, a condition in which increased intrarenal pressure causes hypertension, appears to provide a unifying framework to explain the complex pathophysiology. Page kidney hypertension is renin-mediated acutely and ischemia-mediated chronically. Renal venous outflow obstruction also causes a Page kidney phenomenon, providing a hypothesis for the increased vulnerability of a subset of women who have what we are hypothesizing is a "renal compartment syndrome" due to inadequate ipsilateral collateral renal venous circulation consistent with well-known variation in normal venous anatomy...
September 15, 2016: Journal of the American Society of Hypertension: JASH
Gopal Krushna Pal, Chandrasekaran Adithan, Gurusamy Umamaheswaran, Pravati Pal, Nivedita Nanda, Jagadeeswaran Indumathy, Avupati Naga Syamsunder
Though endothelial nitric oxide synthase (eNOS) gene polymorphism is documented in the causation of hypertension, its role in prehypertension has not been investigated. The present study was conducted in 172 subjects divided into prehypertensives (n = 57) and normotensives (n = 115). Cardiovascular (CV) parameters including baroreflex sensitivity (BRS) by continuous BP variability assessment and sympathovagal imbalance (SVI) by heart rate variability analysis were recorded. Biochemical parameters for insulin resistance (homeostatic model for assessment of insulin resistance), oxidative stress, lipid risk factors, renin, and inflammatory parameters were measured...
September 15, 2016: Journal of the American Society of Hypertension: JASH
Lise H Nielsen, Per Ovesen, Mie R Hansen, Steven Brantlov, Bente Jespersen, Peter Bie, Boye L Jensen
It was hypothesized that primary renal sodium retention blunted the reactivity of the renin-angiotensin-aldosterone system to changes in salt intake in preeclampsia (PE). A randomized, cross-over, double-blinded, dietary intervention design was used to measure the effects of salt tablets or placebo during low-salt diet in PE patients (n = 7), healthy pregnant women (n = 15), and nonpregnant women (n = 13). High-salt intake decreased renin and angiotensin II concentrations significantly in healthy pregnant women (P < ...
November 2016: Journal of the American Society of Hypertension: JASH
Daniel Levy
No abstract text is available yet for this article.
November 2016: Journal of the American Society of Hypertension: JASH
Stephen E Asche, Patrick J O'Connor, Steven P Dehmer, Beverly B Green, Anna R Bergdall, Michael V Maciosek, Rachel A Nyboer, Pamala A Pawloski, JoAnn M Sperl-Hillen, Nicole K Trower, Karen L Margolis
This paper reports subgroup analysis of a successful cluster-randomized trial to identify attributes of hypertensive patients who benefited more or less from an intervention combining blood pressure (BP) telemonitoring and pharmacist management. The end point was BP < 140/90 mm Hg at 6-month follow-up. Fourteen baseline patient characteristics were selected a priori as subgroup variables. Among the 351 trial participants, 44% were female, 84% non-Hispanic white, mean age was 60.9 years, and mean BP was 149/86 mm Hg...
November 2016: Journal of the American Society of Hypertension: JASH
William E Haley, Olivia N Gilbert, Robert F Riley, Jill C Newman, Christianne L Roumie, Jeffrey Whittle, Ian M Kronish, Leonardo Tamariz, Alan Wiggers, Donald E Morisky, Molly B Conroy, Eugene Kovalik, Nancy R Kressin, Paul Muntner, David C Goff
We examined baseline data from the Systolic Blood Pressure Intervention Trial (SPRINT) to investigate whether medication adherence, measured by the 8-item Morisky Medication Adherence Scale (MMAS-8), was associated with systolic blood pressure (SBP) and whether MMAS-8 score and number of antihypertensive medications interacted in influencing SBP. A total of 8435 SPRINT participants were included: 21.2% had low adherence (MMAS-8: <6); 40.0% had medium adherence (6 to <8); and 38.8% had high adherence (8)...
November 2016: Journal of the American Society of Hypertension: JASH
Sungha Park, Ping Yan, César Cerezo, Barrett W Jeffers
This post hoc analysis of CAMELOT and PREVENT analyzed the impact of blood pressure variability (BPV, assessed as within-subject standard deviation of SBP from 12 weeks onward) on the incidence of major adverse cardiovascular events (MACE, defined according to original studies). Patients (n = 1677 CAMELOT; n = 776 PREVENT) were stratified by BPV quartile. Regardless of study, BPV was significantly lower for amlodipine versus other treatments. In CAMELOT, a significant association between BPV quartile and MACE was observed with amlodipine treatment...
October 2016: Journal of the American Society of Hypertension: JASH
Barbara Pręgowska-Chwała, Aleksander Prejbisz, Marek Kabat, Bogna Puciłowska, Katarzyna Paschalis-Purtak, Elżbieta Florczak, Anna Klisiewicz, Beata Kuśmierczyk-Droszcz, Katarzyna Hanus, Michael Bursztyn, Andrzej Januszewicz
The purpose of the study was to evaluate the degree of morning blood pressure surge (MBPS) and its relationship with markers of cardiovascular alterations in untreated middle-aged hypertensives. We studied 241 patients (mean age, 36.6 ± 10.7 years). Subjects with higher sleep-through MBPS (st-MBPS) were older (P = .003), had higher carotid intima-media thickness (cIMT) (P = .05) and lower E/A ratio (P = .01) than those with lower MBPS. Subjects with higher prewakening MBPS (pw-MBPS) had significantly higher deceleration time (P = ...
October 2016: Journal of the American Society of Hypertension: JASH
Michael J Bloch
No abstract text is available yet for this article.
October 2016: Journal of the American Society of Hypertension: JASH
Silvia Totaro, Franco Rabbia, Alberto Milan, Elaine M Urbina, Franco Veglio
Aortic root dilatation is associated with increased cardiovascular risk in hypertensive adults. In the young, few data have been published evaluating the cardiovascular organ damage that may be present in patients with aortic dilatation. The objective was to evaluate the prevalence of proximal aorta dilatation, its possible determinants, and its relation with target organ damage in young subjects. The aorta was measured at the level of the sinus of valsalva and at its proximal ascending aorta (pAA) in a total of 177 young subjects (11-35 years)...
October 2016: Journal of the American Society of Hypertension: JASH
Javad Momeni, Abdollah Omidi, Fariba Raygan, Hossein Akbari
This study aimed at assessing the effects of mindfulness-based stress reduction (MBSR) on cardiac patients' blood pressure (BP), perceived stress, and anger. In total, 60 cardiac patients were recruited between April and June 2015 from a specialized private cardiac clinic located in Kashan, Iran. Patients were allocated to the intervention and control groups. Patients in the experimental group received MBSR in eight 2.5-hour sessions, while patients in the control group received no psychological therapy. The main outcomes were BP, perceived stress, and anger...
October 2016: Journal of the American Society of Hypertension: JASH
Horacio Kaufmann, Lucy Norcliffe-Kaufmann, L Arthur Hewitt, Gerald J Rowse, William B White
The prodrug droxidopa increases blood pressure (BP) in patients with neurogenic orthostatic hypotension. The BP profile of droxidopa in neurogenic orthostatic hypotension patients (n = 18) was investigated using ambulatory BP monitoring. Following dose optimization and a washout period, 24-hour "off-drug" data were collected. "On-drug" assessment was conducted after 4-5 weeks of droxidopa treatment (mean dose, 444 mg, three times daily). Ambulatory monitoring off drug revealed that 90% of patients already had abnormalities in the circadian BP profile and did not meet criteria for normal nocturnal BP dipping...
October 2016: Journal of the American Society of Hypertension: JASH
Stuart Isaacson, Steven Vernino, Adam Ziemann, Gerald J Rowse, Uwa Kalu, William B White
The long-term safety of droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Parkinson disease, pure autonomic failure, multiple system atrophy, or nondiabetic autonomic neuropathy was evaluated in a phase 3, multinational, open-label study in patients who previously participated in a double-blind, placebo-controlled clinical trial of droxidopa. A total of 350 patients received droxidopa 100 to 600 mg three times daily. Mean duration of droxidopa exposure was 363 days (range, 2-1133 days)...
October 2016: Journal of the American Society of Hypertension: JASH
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"